


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1-2. (Cancelled)
3. (Previously Presented) A compound according to claim 6, in which  
A or B in each case independently of one another represent hydrogen, tetrazolyl or the group  $-N(CH_3)_2$ ,  $-NH-(CO)-pyrrolidinyl$ ,  $-NH-(CO)-pentyl$ ,  $-NH-(CO)-hexyl$ ,  $-NH-(CO)-hexyl-NH_2$ ,  $-NH-(CO)-C_3H_7$ ,  $-NH-(CO)-CH_2-phenyl$ ,  $-NH-(CO)-CH_2-NH_2$ ,  $-NH-(CO)-C_2H_4-NH_2$ ,  $-NH-(CO)-CH(NH_2)-CH_3$ ,  $-NH-(CO)-CH(NH_2)-hydroxyphenyl$ ,  $-NH-(CO)-CH(NH_2)-CH_2-phenyl$ ,  $-NH-(CO)-CH(NH_2)-CH_2-hydroxyphenyl$ ,  $-NH-(CO)-CH(NH-(CO)-CH_3)-CH_2-phenyl$ ,  $-NH-(CO)-CH_2-NH-(CO)-CH_3$ ,  $-NH-(CO)-N(C_2H_5)(C_2H_4-piperidinyl)$ ,  $-NH-(CO)-N(CH_3)(C_2H_4-piperidinyl)$ ,  $-NH-(CO)-CH_2-NH(CH_3)$ ,  $-CH_2-N(CH_3)_2$ ,  $-NH-(CO)NH-CH_2-COOH$ , hydantoinyl,  $-CH_2-COOH$   
wherein pyrrolidinyl can optionally be substituted with hydroxy or the group  $-NH_2$ ,  $-N(CH_3)_2$  or  $-NH-(CO)-CH_3$ ,  
and wherein hydantoinyl can be substituted with  $-CH_3$ ,  $-CH_2-COOH$ , or  $-(CO)-thiazolidinonyl$ ,  
X represents or the group  $-NH-$ ,  
R<sup>1</sup> represents halogen and  
R<sup>2</sup> represents hydrogen or the group  $-NH-(CO)-phenyl$   
or  $-C_2H_4-$ ,  $-C_3H_6-$  both can optionally be substituted in one or more places, the same way or differently, with cyano, hydroxy, phenyl, naphthyl, imidazolyl, thiazolyl, pyridyl, 2-oxazoliny, piperidinyl,  $-NH_2$ ,  $-NH-CH_2-thienyl$ ,  $-NH-pyridinyl-NO_2$ ,  $-NH-thiazolyl$ ,  $-SO_2-thienyl$ ,  $-SO_2-NH_2$ ,  $-SO_2-CH_3$ ,  $-SO_2-C_3H_7$ , pyrrolidinonyl substituted with  $-COOH$ ,  $-NH-(CO)-NH-thienyl$ ,  $-NH-(CO)-NH-phenyl$ ,  $-NH-(CO)-NH-C_2H_5$ ,  $-NH-(CO)-C(CH_3)_3$ ,  $-NH-(CO)-S-C_2H_5$ ,  $-NH-(CS)-NH-C_2H_5$ ,  $-NH-(CO)-C_2H_5$ ,  $-NH-(CO)-thienyl$ ,  $-(CO)-NH-NH_2$ ,  $-(CO)-NH-CH_2-$

(CO)-NH<sub>2</sub>, -(CO)-NH-C<sub>2</sub>H<sub>5</sub>, -COOH, wherein phenyl or imidazolyl, thiazolyl can optionally be substituted in one or more places, the same way or differently, with hydroxy, -CH<sub>3</sub>, -NH-(CO)-CH<sub>2</sub>-NH<sub>2</sub>, -COOC<sub>2</sub>H<sub>5</sub>, -COOC(CH<sub>3</sub>)<sub>3</sub>,



or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.


4. (Previously Presented) A compound according to claim 6, in which  
A or B in each case independently of one another represent hydrogen or the group -NH-

(CO)-pyrrolidinyl, -NH-(CO)-piperidinyl, -NH-(CO)-morpholinyl, -NH-(CO)-hexyl-NH<sub>2</sub>, -NH-(CO)-CH(NH<sub>2</sub>)-hydroxyphenyl, -NH-(CO)-CH(NH<sub>2</sub>)-CH<sub>2</sub>-hydroxyphenyl, hydantoin optionally substituted with -CH<sub>3</sub>,

X represents or the group -NH-,

R<sup>1</sup> represents halogen and

R<sup>2</sup> represents hydrogen, -C<sub>2</sub>H<sub>4</sub>-imidazolyl or -C<sub>3</sub>H<sub>7</sub> which can optionally be substituted in one or more places, the same way or differently with the group -NH-CH<sub>2</sub>-thienyl, -NH-(CO)-C<sub>2</sub>H<sub>5</sub>, -NH-(CO)-C(CH<sub>3</sub>)<sub>3</sub>,




or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

5. (Previously Presented) A compound according to claim 4, which is  
N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
N-[3-[[5-bromo-4-[[3-[[1-oxo-3-(phenylsulfonyl)propyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,  
N-[3-[[4-[[3-[(1-aminocyclopentyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
N-[3-[[4-[[3-[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-iodo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
N<sup>1</sup>-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopentanedicarboxamide,  
(4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,  
(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,  
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,  
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,  
N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N-ethyl-N-[2-(1-piperidinyl)ethyl]-urea,  
N-[3-[[5-bromo-4-[[3-[(2,2-dimethyl-1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
N-[3-[[2-[[3-[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[2-[[3-[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,  
 N-[3-[[2-[[3-[(2S)-2-amino-2-phenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,  
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,  
 N-[3-[[2-[[3-[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,  
 N<sup>1</sup>-[3-[[5-bromo-2-[[3-[(2S)-2-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopropanedicarboxamide,  
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,  
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,  
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,  
 N-(3-((5-bromo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,  
 N1-(3-((5-bromo-2-((3-((1-pyrrolidinylcarbonyl)amino)phenyl)amino)-4-pyrimidinyl)-amino)propyl)-1,1-cyclopropanedicarboxamide,  
 N-(3-((5-bromo-4-((3-((1-oxopropyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,  
 N-(3-((5-iodo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,  
 N-[3-[[5-bromo-4-[[3-[[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
 N-[3-[[5-bromo-4-[[3-[[[(2S)-4-oxo-2-azetidyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
 (4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or


N-[3-[[4-[[3-[[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,  
or a pharmaceutically acceptable salt thereof.

6. (Currently Amended) A compound of formula (I)



in which

A or B	in each case independently of one another represent hydrogen or the group $-\text{NO}_2$ , $-\text{NH}_2$ , $-\text{NR}^3\text{R}^4$ , $-\text{N}(\text{C}_{1-6}\text{-hydroxyalkyl})_2$ , $-\text{NH}(\text{CO})-\text{R}^5$ , $-\text{NHCOOR}^6$ , $-\text{NR}^7-(\text{CO})-\text{NR}^8\text{R}^9$ , $-\text{NR}^7-(\text{CS})-\text{NR}^8\text{R}^9$ , $-\text{COOR}^5$ , $-\text{CO}-\text{NR}^8\text{R}^9$ , $-\text{SO}_2-\text{CH}_3$ , 4-bromo-1-methyl-1 <i>H</i> -pyrazolo-3-yl or $\text{C}_{1-6}$ -alkyl optionally substituted in one or more places, the same way or differently with cyano, halogen, hydroxy or the group $-\text{NH}_2$ , $-\text{NH}(\text{CO})-\text{R}^5$ , $-\text{SO}_2-\text{NHR}^3$ , $-\text{COOR}^5$ , $-\text{CONR}^8\text{R}^9$ , $-\text{O}(\text{CO})-\text{R}^5$ , $-\text{O}(\text{CO})-\text{C}_{1-6}\text{-alkyl}-\text{R}^5$ ,
X	represents an oxygen atom or the group $-\text{NH}-$ ,
$\text{R}^1$	represents hydrogen, halogen, hydroxymethyl or the group $-\text{COOH}$ , $-\text{COO}-\text{iso-propyl}$ , $-\text{NO}_2$ , $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{COOH}$ or $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{COO}-\text{C}_{1-6}\text{-alkyl}$ ,
$\text{R}^2$	represents $\text{C}_{1-6}$ -alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group $-\text{NH}_2$ , $-\text{NH}(\text{CO})\text{O}-\text{CH}_2\text{-phenyl}$ , $-\text{NH}(\text{CO})\text{H}$ , $-\text{NH}(\text{CO})\text{-phenyl}$ , $-\text{NH}(\text{CO})\text{-CH}_2\text{-O-phenyl}$ , $-\text{NH}(\text{CO})\text{-CH}_2\text{-phenyl}$ , $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{CH}_2\text{-phenyl}$ , $-\text{NH}(\text{CO})\text{-CH}_2\text{-CH}(\text{CH}_3)\text{-phenyl}$ , $-\text{NH}(\text{CO})\text{-CH}(\text{NH}_2)\text{-(CH}_2)_2\text{-COOH}$ ,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C<sub>1-6</sub>-alkyl or -(CO)-C(CH<sub>2</sub>)-C<sub>2</sub>H<sub>5</sub>, or represents C<sub>3</sub>-alkynyl,

R<sup>3</sup> or R<sup>4</sup> in each case independently of one another represent hydrogen or C<sub>1-6</sub>-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, phenyl or hydroxyphenyl,

or

R<sup>3</sup> and R<sup>4</sup> together form a C<sub>3-6</sub>-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more -(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C<sub>3-6</sub>-heterocycloalkylring can optionally be substituted with C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkyl-COOH or C<sub>1-6</sub>-alkyl-NH<sub>2</sub>,

R<sup>5</sup> represents C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>3-6</sub>-cycloalkyl or phenyl each can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy, phenyl or with the group -NH<sub>2</sub>, -NH(CO)-O-C<sub>1-6</sub>-alkyl, wherein phenyl can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy or C<sub>1-6</sub>-alkyl,

R<sup>6</sup> represents C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl or phenyl,

$R^7$  represents hydrogen or  $C_{1-6}$ -alkyl and  
 $R^8$  or  $R^9$  in each case independently of one another represent hydrogen,  $C_{1-6}$ -alkyl,  $C_{2-6}$ -alkenyl,  $C_{3-6}$ -cycloalkyl, aryl or phenyl, wherein aryl or phenyl can optionally be substituted in one or more places, the same way or differently, with hydroxy or the group  $-NO_2$  or  $-N(C_{1-6}\text{-alkyl})_2$   
 or  
 $R^8$  and  $R^9$  together form a  $C_{3-6}$ -heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more  $-(CO)-$  groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the  $C_{3-6}$ -heterocycloalkylring can optionally be substituted with the group  $-NH_2$ ,  
 wherein when A and B represent hydrogen, X represents  $-NH-$  and  $R^2$  represents  $C_{1-6}$ -alkyl,  
 then  $R^1$  represents  $-NH-(CO)-CH(NH_2)-(CH_2)_2-COOH$  or  $-NH-(CO)-CH(NH_2)-(CH_2)_2-COOC_2H_5$ ,  
 wherein when  $R^1$  represents  $-COO$ -iso-propyl,  
 then X represents  $-NH-$  and  $R^2$  represents  $C_3$ -alkinyl and A or B independently of one another represent the group  $-NO_2$  or  $-NH-(CO)-CF_3$ , and  
 wherein when  $R^1$  represents halogen, X represents  $-NH-$ , B represents hydrogen and  $R^2$  represents  $C_{1-6}$ -alkyl substituted with  $-NH_2$ ,  
 then A represents  $-NH-(CO)-C_6\text{-cycloalkyl}-NH_2$ ,

or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

7. (Previously Presented) A compound according to claim 6, in which  
 A or B in each case independently of one another represent hydrogen or the group  $-NH-C_2H_4-OH$ ,  $-NH-CH_2$ -hydroxyphenyl,  $-NH-(CO)$ -pyrrolidinyl,  $-NH-(CO)-CH(NH_2)-CH_2$ -phenyl,  $-NH-(CO)$ -pentyl- $NH_2$ ,  $-NH-(CO)$ -hexyl- $NH_2$ ,  $-NH-(CO)-CH_2-NH_2$ ,  $-NH-(CO)-CH(NH_2)$ -hydroxyphenyl,  $-NH-(CO)-CH_2$ -hydroxyphenyl,  $-NH-(CO)-CH_2$ -methylphenyl,  $-NH-(CO)-C_2H_4$ -dihydroxyphenyl,  $-NH-(CO)-$




CH(OH)-phenyl, -NH-(CO)-CH(NH<sub>2</sub>)-CH<sub>2</sub>(OH), -NH-(CO)-C(CH<sub>3</sub>)<sub>2</sub>NH<sub>2</sub>, -NH-(CO)-NH(C<sub>2</sub>H<sub>5</sub>), -CH<sub>2</sub>OH, -(CO)-NH-cyclopropyl, -(CO)-NH-CH(CH<sub>3</sub>)<sub>2</sub>, wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -NH<sub>2</sub>,

X represents an oxygen atom or the group -NH-,

R<sup>1</sup> represents halogen or hydroxymethyl and

R<sup>2</sup> represents -C<sub>2</sub>H<sub>5</sub> optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or represents -C<sub>3</sub>H<sub>7</sub> or -C<sub>4</sub>H<sub>8</sub> optionally substituted in one or more places, the same way or differently with the group -NH<sub>2</sub>, -NH-(CO)-CH(NH<sub>2</sub>)-C<sub>2</sub>H<sub>4</sub>-COOH, -NH-(CO)-phenyl, -NH-(CO)-CH<sub>2</sub>-phenyl, -NH-(CO)-CH<sub>2</sub>-CH(CH<sub>3</sub>)-phenyl, -NH-(CO)-CH<sub>2</sub>-O-phenyl, -NH-(CO)-O-CH<sub>2</sub>-phenyl, -NH-(CO)-CH(NH<sub>2</sub>)CH<sub>2</sub>-phenyl,



wherein phenyl can optionally be substituted in one or more places, the same or differently, with halogen, -CH<sub>3</sub> or -(CO)-C(CH<sub>2</sub>)(C<sub>2</sub>H<sub>5</sub>), or represents C<sub>3</sub>-alkinyl,

or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

8. (Previously Presented) A compound according to claim 7, which is

*N*-[3-[[2-[[3-[(2*R*)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

1-[3-[[2-[[3-[(2*R*)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,

*N*-[3-[[5-bromo-4-[[3-[(5-oxo-2-pyrrolidinyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-dichloro-phenyl)-acetyl-amino]-propyl-amino}-pyrimidin-2-yl-amino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(4-bromo-phenyl)-acetyl-amino]-propyl-amino}-pyrimidin-2-yl-amino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(2-*p*-tolyl-acetyl-amino)-propyl-amino]-pyrimidin-2-yl-amino}-phenyl)-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-difluoro-phenyl)-acetyl-amino]-propyl-amino}-pyrimidin-2-yl-amino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid {3-[5-bromo-4-(3-{2-[2,3-dichloro-4-(2-methylene-butyl)-phenoxy]-acetyl-amino}-propyl-amino)-pyrimidin-2-yl-amino]-phenyl}-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[3-(2,3-dichloro-phenyl)-butyl-amino]-propyl-amino}-pyrimidin-2-yl-amino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(3-bromo-benzoyl-amino)-propyl-amino]-pyrimidin-2-yl-amino}-phenyl)-amide,

*N*-(3-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

*N*-[3-[[2-[[3-[(2*R*)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

*N*-[3-[[2*S*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyl)oxy]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,


*N*-[3-[[2*R*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyl)oxy]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,

( $\alpha$ R)- $\alpha$ -Amino-N-[3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-(hydroxymethyl)phenyl]benzenepropanamide,  
 2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-5-hydroxymethyl-phenylamino]-ethanol,  
 (2R)-Amino-N-[3-hydroxymethyl-5-(4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,  
 3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)- N-cyclopropyl-benzamide,  
 3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-N-isopropyl-benzamide,  
 Phenylmethyl [3-[[2-[[3-[[[(ethylamino)carbonyl]amino]phenyl]amino]-5-(hydroxymethyl)pyrimidine-4-yl]amino]propyl]carbamate,  
 Pyrrolidine-1-carboxylic acid (3-{4-[3-((2R)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,  
 Pyrrolidine-1-carboxylic acid (3-{4-[3-((2S)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,  
 2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-ethanol,  
 1-Amino-cyclopentancarbonylic acid[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,  
 1-Amino-cyclohexancarbonylic acid-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,  
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,  
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,  
 2-{[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-methyl}-phenol,  
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,  
 N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(3,4-dihydroxy-phenyl)-propionamide,

N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2S)-phenyl-acetamide,  
 N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2R)-phenyl-acetamide,  
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-hydroxy-propionamide,  
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-phenyl]-3-hydroxy-propionamide,  
 2-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-methyl-propionamide,  
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,  
 (2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide or  
 (2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide,  
 or a pharmaceutically acceptable salt thereof.

9. (Previously Presented) A compound according to claim 6, in which  
 A or B in each case independently of one another represent halogen, hydrogen or the group -SO<sub>2</sub>-CH<sub>3</sub>, -NO<sub>2</sub>, -NH<sub>2</sub>, -CF<sub>3</sub>, -CH<sub>2</sub>-NH-(CO)-NH<sub>2</sub>, -CH<sub>2</sub>-pyrrolidinyl, -NH-(CO)-CH<sub>3</sub>, -NH-(CO)-hexyl-NH<sub>2</sub>, -NH-(CO)-phenyl, -NH-(CO)-pyrrolidinyl, --NH-(CO)-CH(NH<sub>2</sub>)-CH<sub>2</sub>-phenyl, NH-(CO)-OCH<sub>3</sub>, -NH-(CO)-OCH(CH<sub>3</sub>)<sub>2</sub>, -NH-(CO)-OC<sub>2</sub>H<sub>4</sub>-morpholino, -NH-(CO)-NH-cyclopropyl, -NH-(CO)-morpholino, -NH-(CO)-NH-C<sub>2</sub>H<sub>4</sub>-morpholino, -NH-(CO)-NH-hydroxycycloalkyl, hydantoinyl,  
 wherein pyrrolidinyl can optionally be substituted with hydroxy or the group -NH<sub>2</sub> and  
 wherein hydantoinyl can optionally be substituted with the group -CH<sub>3</sub> or -(CO)-thiazolidinonyl,

X represents the group  $-NH-$ ,  
 $R^1$  represents halogen and  
 $R^2$  represents  $-CH_2$ -dihydroxyphenyl,  $-C_2H_4$ -imidazolyl, or  $-C_3H_7$  optionally substituted in one or more places, the same way or differently, with



or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

10. (Previously Presented) A compound, which is  
 4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,  
 N-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-  
 urea,  
 1-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-3-  
 pyrrolidinol,  
 (3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid  
 methyl ester,  
 N2-(3-aminophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,  
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-  
 cyclopropyl-urea,  
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-  
 morpholinecarboxamide,  
 (3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid  
 1-methylethyl ester,  
 N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-

methanesulfonamide,  
N2-(3-amino-5-(trifluoromethyl)phenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,  
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(2-(4-morpholinyl)ethyl)-urea,  
N2-(3-amino-5-chlorophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,  
(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid 2-(4-morpholinyl)ethyl ester,  
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(4-hydroxycyclohexyl)-urea,  
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-acetamide,  
N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-benzamide,  
(4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,  
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,  
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,  
1-[3-[[2-[[3-[[2-(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,  
1-[3-[[2-[[3-[[1-(aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,  
N-[3-[[2-[[3-[[2-(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,  
N-[3-[[2-[[3-[[2-(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,  
3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,  
3-[3-[[5-bromo-4-[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,

(4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,  
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,  
 N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,  
 3-[3-[[5-bromo-4-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,  
 (4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or  
 (4R)-N-[3-[[5-bromo-2-[[3-[2,5-dioxo-3-[[4R)-2-oxo-4-thiazolidinyl]carbonyl]-1-imidazolidinyl]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,  
 or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) A compound, which is  
 N-(3-((4-((3-(aminomethyl)phenyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,  
 4-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1-naphthaleneacetic acid,  
 5-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1H-indole-2-carboxylic acid, ethyl ester,  
 5-bromo-N4-[2-(1H-imidazol-5-yl)ethyl]-N2-(2-methyl-6-quinolinyl)-2,4-pyrimidinediamine,  
 4-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,  
 4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,  
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,  
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,  
 5-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-1,3-dihydro-2H-benzimidazol-2-one,  
 3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzoic acid methyl ester,

3-amino-5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,

*N*-((3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-methanesulfonamide,

4-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,

3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-phenol,

5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-*1H*-isoindole-1,3(2H)-dione,

5-bromo-*N*<sup>4</sup>-(2-(*1H*-imidazol-4-yl)ethyl)-*N*<sup>2</sup>-(3-methylphenyl)-2,4-pyrimidinediamine,

*N*-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-methanesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-methyl-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((3-aminopropyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((3-(*1H*-imidazol-1-yl)propyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(1-pyrrolidinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid,

4-((4-((3-((aminocarbonyl)amino)propyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid ethyl ester,

4-((5-bromo-4-((4-(methylamino)butyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(*1H*-imidazol-1-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-ethyl-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(2-pyridinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(*1H*-indol-3-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,



2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-acetamide,  
*N*-(2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)ethyl)-acetamide,  
 3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-propanamide,  
*N*-(4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)butyl)-acetamide,  
*N*-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-acetamide,  
*N*-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-furancarboxamide,  
*N*-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-1*H*-pyrrole-2-carboxamide,  
 4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanamide,  
*N*-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-thiophenecarboxamide,  
 4-((4-(4-(aminomethyl)-1-piperidinyl)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,  
 4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-*N,N*-dimethylaminosulfonylamin,  
 1-Methyl-1*H*-imidazol-4-sulfonic acid [4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-amid,  
 3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,  
 4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,  
 2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,  
 2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenol,  
 4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid methyl ester,  
 3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,  
 2-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,  
 3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,  
 4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,  
 4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,  
 Methyl 3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-[(2-hydroxyethyl)amino]benzoate,  
 Methyl 3-amino-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]benzoate or

3-[Bis-(2-hydroxy-ethyl)-amino]-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid methyl ester,  
or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 6 and a pharmaceutically acceptable carrier, diluent or excipient.

13-16. (Cancelled)

17. (Previously Presented) A method of treating cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

18. (Previously Presented) A method according to claim 17, wherein the cancer treated is a solid tumor, a tumor- or metastasis growth, Kaposi Sarkom, Hodgkin's disease or leukemia.

19. (Previously Presented) A method according to claim 17, wherein the patient treated is a mammal.

20. (Previously Presented) A method of claim 19, wherein the mammal is a human.

21-25. (Cancelled)

26. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 11 and a pharmaceutically acceptable carrier, diluent or excipient.

27. (Previously Presented) A method of treating cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 26.

28. (Previously Presented) A method according to claim 27, wherein the cancer treated is a solid tumor, a tumor- or metastasis growth, Kaposi Sarkom, Hodgkin's disease or leukemia.

29. (Previously Presented) A method of treating rheumatoid arthritis comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

30-31. (Cancelled)

32. (Previously Presented) A compound according to claim 6, wherein X represents an oxygen atom.


33. (Previously Presented) A compound according to claim 6, wherein X represents the group -NH-.

34. (New) A compound according to claim 6, wherein  
A or B in each case independently of one another represent hydrogen or the group -NO<sub>2</sub>, -NH<sub>2</sub>, -NR<sup>3</sup>R<sup>4</sup>, -N(C<sub>1-6</sub>-hydroxyalkyl)<sub>2</sub>, -NH(CO)-R<sup>5</sup>, -NHCOOR<sup>6</sup>, -NR<sup>7</sup>-(CO)-NR<sup>8</sup>R<sup>9</sup>, -NR<sup>7</sup>-(CS)-NR<sup>8</sup>R<sup>9</sup>, -CO-NR<sup>8</sup>R<sup>9</sup>, -SO<sub>2</sub>-CH<sub>3</sub>, 4-bromo-1-methyl-1H-pyrazolo-3yl or C<sub>1-6</sub>-alkyl optionally substituted in one or more places, the same way or differently with cyano, hydroxy or the group -NH<sub>2</sub>, -NH-(CO)-R<sup>5</sup>, -SO<sub>2</sub>-NHR<sup>3</sup>, -COOR<sup>5</sup>, -CONR<sup>8</sup>R<sup>9</sup>, -O-(CO)-R<sup>5</sup>, -O-(CO)-C<sub>1-6</sub>-alkyl-R<sup>5</sup>.

35. (New) A compound according to claim 6, wherein  
R<sup>1</sup> represents hydrogen, hydroxymethyl or the group -COOH, -COO-iso-propyl, -

NO<sub>2</sub>, -NH-(CO)-(CH<sub>2</sub>)<sub>2</sub>-COOH or -NH-(CO)-(CH<sub>2</sub>)<sub>2</sub>-COO-C<sub>1-6</sub>-alkyl.

36. (New) A compound according to claim 6, wherein R<sup>2</sup> represents C<sub>1-6</sub>-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group -NH-(CO)O-CH<sub>2</sub>-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, -NH-(CO)-CH<sub>2</sub>-O-phenyl, -NH-(CO)-CH<sub>2</sub>-phenyl, -NH-(CO)-CH(NH<sub>2</sub>)CH<sub>2</sub>-phenyl, -NH-(CO)-CH<sub>2</sub>-CH(CH<sub>3</sub>)-phenyl, -NH-(CO)-CH(NH<sub>2</sub>)-(CH<sub>2</sub>)<sub>2</sub>-COOH,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C<sub>1-6</sub>-alkyl or -(CO)-C(CH<sub>3</sub>)<sub>2</sub>-C<sub>2</sub>H<sub>5</sub>, or represents C<sub>3</sub>-alkynyl.

37. (New) A method of treating Kaposi Sarkom, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

38. (New) A method of treating Kaposi Sarkom, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 26.